{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:37:05Z","timestamp":1768441025759,"version":"3.49.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,9,22]],"date-time":"2011-09-22T00:00:00Z","timestamp":1316649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s10620-011-1854-0","type":"journal-article","created":{"date-parts":[[2011,9,21]],"date-time":"2011-09-21T13:36:03Z","timestamp":1316612163000},"page":"9-18","source":"Crossref","is-referenced-by-count":19,"title":["Novel Medical Therapies of Recurrent and Metastatic Gastroenteropancreatic Neuroendocrine Tumors"],"prefix":"10.1007","volume":"57","author":[{"given":"M. D.","family":"Miljkovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Girotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. R.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. B.","family":"Erlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,22]]},"reference":[{"key":"1854_CR1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1572-0241.2007.01777.x","volume":"103","author":"CG Toumpanakis","year":"2008","unstructured":"Toumpanakis CG, Caplin ME. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol. 2008;103:729\u2013732.","journal-title":"Am J Gastroenterol"},{"key":"1854_CR2","first-page":"426","volume":"1","author":"S Oberndorfer","year":"1907","unstructured":"Oberndorfer S. Karzinoid tumore des Dunndarms. Frankf Z Pathol. 1907;1:426\u2013430.","journal-title":"Frankf Z Pathol"},{"key":"1854_CR3","first-page":"237","volume":"25","author":"A Gosset","year":"2009","unstructured":"Gosset A, Masson P. Tumeurs endocrines se l\u2019appendice. Presse Med. 2009;25:237\u2013240.","journal-title":"Presse Med"},{"key":"1854_CR4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bpg.2005.03.006","volume":"19","author":"R Arnold","year":"2005","unstructured":"Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol. 2005;19:491\u2013505.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1854_CR5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1586\/14737140.3.6.863","volume":"3","author":"K Oberg","year":"2003","unstructured":"Oberg K. Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther. 2003;3:863\u2013877.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1854_CR6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MED.0b013e328320d845","volume":"16","author":"AT Phan","year":"2009","unstructured":"Phan AT, Yao JC. Neuroendocrine tumors: current and future medical therapies. Curr Opin Endocrinol Diabetes Obes. 2009;16:72\u201378.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1854_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.sla.0000129342.67174.67","volume":"240","author":"MA Maggard","year":"2004","unstructured":"Maggard MA, O\u2019Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240:117\u2013122.","journal-title":"Ann Surg"},{"key":"1854_CR8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","volume":"9","author":"I Modlin","year":"2008","unstructured":"Modlin I, Oberg K, Chung D, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61\u201372.","journal-title":"Lancet Oncol"},{"key":"1854_CR9","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"J Yao","year":"2008","unstructured":"Yao J, Hassan M, Phan A, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063\u20133072.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"1854_CR10","first-page":"S43","volume":"3","author":"M Kulke","year":"2009","unstructured":"Kulke M, Scher\u00fcbl H. Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2009;3(Suppl 2):S43\u2013S47.","journal-title":"Gastrointest Cancer Res"},{"key":"1854_CR11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.suc.2009.06.008","volume":"89","author":"JL Pasieka","year":"2009","unstructured":"Pasieka JL. Carcinoid tumors. Surg Clin North Am. 2009;89:1123\u20131137.","journal-title":"Surg Clin North Am"},{"key":"1854_CR12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1053\/hupa.2002.129204","volume":"33","author":"S Eeden Van","year":"2002","unstructured":"Van Eeden S, Quaedvlieg PF, Taal BG, et al. Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol. 2002;33:1126\u20131132.","journal-title":"Hum Pathol"},{"key":"1854_CR13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/02841860410018575","volume":"43","author":"K Oberg","year":"2004","unstructured":"Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumors (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol. 2004;43:617\u2013625.","journal-title":"Acta Oncol"},{"key":"1854_CR14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/ejso.2001.1229","volume":"28","author":"M Kawahara","year":"2002","unstructured":"Kawahara M, Kammori M, Kanauchi H, et al. Immunohistochemical prognostic indicators of gastrointestinal carcinoid tumors. Eur J Surg Oncol. 2002;28:140\u2013146.","journal-title":"Eur J Surg Oncol"},{"key":"1854_CR15","first-page":"720","volume":"48","author":"C S\u00f6kmens\u00ebr","year":"2001","unstructured":"S\u00f6kmens\u00ebr C, Gedikoglu G, Uzunalimoglu B. Importance of proliferation markers in gastrointestinal carcinoid tumors: a clinicopathologic study. Hepatogastroenterology. 2001;48:720\u2013723.","journal-title":"Hepatogastroenterology"},{"key":"1854_CR16","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/SMJ.0b013e3181b67356","volume":"102","author":"V Ghevariya","year":"2009","unstructured":"Ghevariya V. Carcinoid tumors of the gastrointestinal tract. South Med J. 2009;102:1032\u20131040.","journal-title":"South Med J"},{"key":"1854_CR17","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","volume":"128","author":"IM Modlin","year":"2005","unstructured":"Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717\u20131751.","journal-title":"Gastroenterology"},{"key":"1854_CR18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.20466","volume":"101","author":"MH Kulke","year":"2004","unstructured":"Kulke MH, Kim H, Clark JW, et al. A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004;101:934\u2013939.","journal-title":"Cancer"},{"key":"1854_CR19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/02841868709113712","volume":"26","author":"K Oberg","year":"1987","unstructured":"Oberg K, Norheim I, Lundqvist G, et al. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin\u2014alone or in combination with 5-FU. Acta Oncol. 1987;26:429\u2013432.","journal-title":"Acta Oncol"},{"key":"1854_CR20","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","volume":"15","author":"K Oberg","year":"2004","unstructured":"Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966\u2013973.","journal-title":"Ann Oncol"},{"key":"1854_CR21","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"S Faiss","year":"2003","unstructured":"Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors\u2013the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689\u20132696.","journal-title":"J Clin Oncol"},{"key":"1854_CR22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","volume":"90","author":"L Kolby","year":"2003","unstructured":"Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003;90:687\u2013693.","journal-title":"Br J Surg"},{"key":"1854_CR23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/CCO.0b013e32833adee2","volume":"22","author":"B Eriksson","year":"2010","unstructured":"Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies. Curr Opin Oncol. 2010;22:381\u2013386.","journal-title":"Curr Opin Oncol"},{"key":"1854_CR24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/02841860310010547","volume":"42","author":"II Schnirer","year":"2003","unstructured":"Schnirer II, Yao JC, Ajani JA. Carcinoid\u2014a comprehensive review. Acta Oncol. 2003;42:672\u2013692.","journal-title":"Acta Oncol"},{"key":"1854_CR25","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1517\/14656566.9.15.2617","volume":"9","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Kidd M, Drozdov I, et al. Pharmacothearpy of neuroendocrine cancers. Expert Opin Pharmacother. 2008;9:2617\u20132626.","journal-title":"Expert Opin Pharmacother"},{"key":"1854_CR26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","volume":"31","author":"IM Modlin","year":"2010","unstructured":"Modlin IM, Pavel M, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31:169\u2013188.","journal-title":"Aliment Pharmacol Ther"},{"key":"1854_CR27","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller H, Schhade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656\u20134663.","journal-title":"J Clin Oncol"},{"key":"1854_CR28","unstructured":"Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology\u2122 for Neuroendocrine Tumors V.1.2011. \u00a9National Comprehensive Cancer Network, Inc 2011. All rights reserved. Accessed July 1, 2011. To view the most recent and complete version of the guideline, go online to www.nccn.org . NATIONAL COMPREHENSIVE CANCER NETWORK\u00ae, NCCN\u00ae, NCCN GUIDELINES\u2122, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc."},{"key":"1854_CR29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","volume":"80","author":"HA Schmid","year":"2004","unstructured":"Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology. 2004;80:47\u201350.","journal-title":"Neuroendocrinology"},{"key":"1854_CR30","doi-asserted-by":"crossref","first-page":"198s","DOI":"10.1200\/jco.2006.24.18_suppl.4082","volume":"24","author":"L Kvols","year":"2006","unstructured":"Kvols L, Wiedenmann B, Oberg K, The SOM230 Carcinoid Study Group, 2006, et al. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study. J Clin Oncol. 2006;24:198s.","journal-title":"J Clin Oncol"},{"key":"1854_CR31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/eje.1.01950","volume":"153","author":"P Jaquet","year":"2005","unstructured":"Jaquet P, Gnerz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH and prolactin secretion from GH-secreting pituitary adenoma classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol. 2005;153:135\u2013141.","journal-title":"Eur J Endocrinol"},{"key":"1854_CR32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","volume":"24","author":"LJ Hofland","year":"2003","unstructured":"Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28\u201347.","journal-title":"Endocr Rev"},{"key":"1854_CR33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/jnci\/djn275","volume":"100","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Moss SF, Chung DC, et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100:1282\u20131289.","journal-title":"J Natl Cancer Inst"},{"key":"1854_CR34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000111501","volume":"87","author":"S Grozinsky-Glasberg","year":"2008","unstructured":"Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology. 2008;87:168\u2013181.","journal-title":"Neuroendocrinology"},{"key":"1854_CR35","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Phan A, Chang D, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311\u20134318.","journal-title":"J Clin Oncol"},{"key":"1854_CR36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69\u201376.","journal-title":"J Clin Oncol"},{"key":"1854_CR37","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1200\/jco.2011.29.15_suppl.4011","volume":"29","author":"JC Yao","year":"2011","unstructured":"Yao JC, Ricci S, Winkler RE, Pavel ME. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): updated safety and efficacy results from RADIANT-2. J Clin Oncol. 2011;29:4011.","journal-title":"J Clin Oncol"},{"key":"1854_CR38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514\u2013523.","journal-title":"N Engl J Med"},{"key":"1854_CR39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2559.1998.00321.x","volume":"32","author":"B Terris","year":"1998","unstructured":"Terris B, Scoazec J, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology. 1998;32:133\u2013138.","journal-title":"Histopathology"},{"key":"1854_CR40","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/cncr.22554","volume":"109","author":"J Zhang","year":"2007","unstructured":"Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer. 2007;109:1478\u20131486.","journal-title":"Cancer"},{"key":"1854_CR41","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327\u2013337.","journal-title":"Clin Cancer Res"},{"key":"1854_CR42","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","volume":"101","author":"AM O\u2019Farrell","year":"2003","unstructured":"O\u2019Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597\u20133605.","journal-title":"Blood"},{"key":"1854_CR43","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","volume":"26","author":"M Kulke","year":"2008","unstructured":"Kulke M, Lenzy N, Meropol J, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403\u20133410.","journal-title":"J Clin Oncol"},{"key":"1854_CR44","unstructured":"Raymond E, Raoul J, Niccoli P, et al. Phase III randomised, double-blind trial of sunitinib versus placebo in patients with progressive, well differentiated malignant islet cell tumours. 11th world congress on gastrointestinal cancer (ESMO 2009); Barcelona, Spain. 2009 June 30\u2013July 03; Abtr 0013."},{"key":"1854_CR45","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/jco.2010.28.15_suppl.4000","volume":"28","author":"P Niccoli","year":"2010","unstructured":"Niccoli P, Raoul J, Bang Y, et al. Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). J Clin Oncol. 2010;28:4000.","journal-title":"J Clin Oncol"},{"key":"1854_CR46","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/jco.2010.28.15_suppl.4003","volume":"28","author":"A Vinik","year":"2010","unstructured":"Vinik A, Bang Y, Raoul J, et al. Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. J Clin Oncol. 2010;28:4003.","journal-title":"J Clin Oncol"},{"key":"1854_CR47","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561\u2013566.","journal-title":"Nat Med"},{"key":"1854_CR48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/02841860902897707","volume":"49","author":"H Kindmark","year":"2010","unstructured":"Kindmark H, Janson ET, Gustafsson B, et al. Five patients with malignant endocrine tumors tested with imatinib mesylate (Gleevec). Acta Oncol. 2010;49:100\u2013101.","journal-title":"Acta Oncol"},{"key":"1854_CR49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/1078-0432.CCR-06-1618","volume":"13","author":"J Yao","year":"2007","unstructured":"Yao J, Zhang J, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007;13:234\u2013240.","journal-title":"Clin Cancer Res"},{"key":"1854_CR50","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2007.12.3901","volume":"25","author":"TJ Hobday","year":"2007","unstructured":"Hobday TJ, Rubin J, Holen K, et al. MCO44h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol. 2007;25:4504.","journal-title":"J Clin Oncol"},{"key":"1854_CR51","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","volume":"26","author":"J Yao","year":"2008","unstructured":"Yao J, Phan P, Hoss H, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26:1316\u20131323.","journal-title":"J Clin Oncol"},{"key":"1854_CR52","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1200\/jco.2010.28.15_suppl.4002","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC, Phan AT, Fogleman D, et al. Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol. 2010;28:4002.","journal-title":"J Clin Oncol"},{"key":"1854_CR53","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082\u20134085.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1854_CR54","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-007-0521-9","volume":"61","author":"KA Varker","year":"2008","unstructured":"Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol. 2008;61:661\u2013668.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1854_CR55","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1200\/jco.2008.26.15_suppl.4611","volume":"26","author":"M Sung","year":"2008","unstructured":"Sung M, Kvols L, Wolin E, et al. Phase II proof-of-concept study of atiprimoid in patients with advanced low-to intermediate-grade neuroendocrine carcinoma. J Clin Oncol. 2008;26:4611.","journal-title":"J Clin Oncol"},{"key":"1854_CR56","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2006.08.8898","volume":"25","author":"A Tolcher","year":"2007","unstructured":"Tolcher A, Rothenberg M, Rodon J, et al. A phase I pharmakinetic and pharmacodynamic study of AMG 479, a fully monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-IR) in advanced solid tumors. J Clin Oncol. 2007;25:3002.","journal-title":"J Clin Oncol"},{"key":"1854_CR57","doi-asserted-by":"crossref","first-page":"14624","DOI":"10.1200\/jco.2008.26.15_suppl.14624","volume":"26","author":"L Anthony","year":"2008","unstructured":"Anthony L, Chester M, Michael S, et al. Phase II open-label clinical trial of vatalanib (PTK\/ZK) in patients with progressive neuroendocrine cancer. J Clin Oncol. 2008;26:14624.","journal-title":"J Clin Oncol"},{"key":"1854_CR58","doi-asserted-by":"crossref","first-page":"14684","DOI":"10.1200\/jco.2008.26.15_suppl.14684","volume":"26","author":"M Pavel","year":"2008","unstructured":"Pavel M, Bartel C, Henck F, et al. Open-label, nonrandomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787\/ZK222584 (PTK\/ZK) in patients with advanced neuroendocrine carcinomas (NEC). J Clin Oncol. 2008;26:14684.","journal-title":"J Clin Oncol"},{"key":"1854_CR59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.beem.2007.01.007","volume":"21","author":"F Forrer","year":"2007","unstructured":"Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab. 2007;21:111\u2013129.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1854_CR60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","volume":"36","author":"R Valkema","year":"2006","unstructured":"Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147\u2013156.","journal-title":"Semin Nucl Med"},{"key":"1854_CR61","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"D Kwekkeboom","year":"2008","unstructured":"Kwekkeboom D, de Herder W, Kam B, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTAO, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124\u20132130.","journal-title":"J Clin Oncol"},{"key":"1854_CR62","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdp372","volume":"21","author":"JB Cwikla","year":"2010","unstructured":"Cwikla JB, Sankowski A, Seklecka N, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2010;21:787\u2013794.","journal-title":"Ann Oncol"},{"key":"1854_CR63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","volume":"31","author":"AS Kennedy","year":"2008","unstructured":"Kennedy AS, Dezarn WA, Mc Neillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Ann J Clin Oncol. 2008;31:271\u2013279.","journal-title":"Ann J Clin Oncol"},{"key":"1854_CR64","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","volume":"13","author":"S Ekeblad","year":"2007","unstructured":"Ekeblad S, Sundin A, Welin S, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13:2986\u20132991.","journal-title":"Clin Cancer Res"},{"key":"1854_CR65","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","volume":"24","author":"MH Kulke","year":"2006","unstructured":"Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401\u2013406.","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"1854_CR66","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1200\/jco.2010.28.15_suppl.4104","volume":"28","author":"PL Kunz","year":"2010","unstructured":"Kunz PL, Kuo T, Zahn JM, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol. 2010;28(15 Suppl):4104.","journal-title":"J Clin Oncol"},{"key":"1854_CR67","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/modpathol.3800427","volume":"18","author":"B Papouchado","year":"2005","unstructured":"Papouchado B, Erickson LA, Rohlinger AL, et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol. 2005;18:1329\u20131335.","journal-title":"Mod Pathol"},{"key":"1854_CR68","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1200\/JCO.2006.07.1878","volume":"24","author":"TJ Hobday","year":"2006","unstructured":"Hobday TJ, Holen K, Donehower R, et al. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol. 2006;24:4043.","journal-title":"J Clin Oncol"},{"key":"1854_CR69","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","volume":"88","author":"M O\u2019Reilly","year":"1997","unstructured":"O\u2019Reilly M, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277\u2013285.","journal-title":"Cell"},{"key":"1854_CR70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1247\/csf.25.97","volume":"25","author":"U Zatterstrom","year":"2000","unstructured":"Zatterstrom U, Felbor U, Fukai N, et al. Collagen XVIII\/endostatin structure and functional role in angiogenesis. Cell Struct Funct. 2000;25:97\u2013101.","journal-title":"Cell Struct Funct"},{"key":"1854_CR71","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2006.05.6762","volume":"24","author":"MH Kulke","year":"2006","unstructured":"Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006;24:3555\u20133561.","journal-title":"J Clin Oncol"},{"key":"1854_CR72","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","volume":"29","author":"MH Kulke","year":"2011","unstructured":"Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the national cancer institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol. 2011;29:934\u2013943.","journal-title":"J Clin Oncol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-011-1854-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-011-1854-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-011-1854-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:08:01Z","timestamp":1712902081000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-011-1854-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,22]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1854"],"URL":"https:\/\/doi.org\/10.1007\/s10620-011-1854-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,22]]}}}